GeoVax Labs, Inc.
Monday, June 03, 2024
Company Presentation
![Immunology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/immunology.png)
Company Presentation Theater 2
GeoVax is a clinical-stage company developing novel therapies and vaccines for solid tumor cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated (i) as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, (ii) as a booster vaccine in patients with chronic lymphocytic leukemia (CLL), and (iii) as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines.
![GeoVax Labs, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1800221-1-JPG.png)
Company Website:
http://www.geovax.com
Lead Product in Development:
GEO-CM04S1 - Next Generation COVID-19 Vaccine
Gedeptin - Therapy for Solid Tumor Cancers
Exchange
Nasdaq
Ticker
GOVX
Company HQ City
Smyrna
Company HQ State
GA
Company HQ Country
United States
CEO/Top Company Official
David Dodd
Development Phase of Primary Product
Phase II
Primary Speaker